551 related articles for article (PubMed ID: 8935399)
1. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
Plosker GL; McTavish D
Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
[TBL] [Abstract][Full Text] [Related]
2. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
Overgaard K; Hansen MA; Jensen SB; Christiansen C
BMJ; 1992 Sep; 305(6853):556-61. PubMed ID: 1393035
[TBL] [Abstract][Full Text] [Related]
3. [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes].
Overgaard K; Ravn P; Hansen MA; Christiansen C
Ugeskr Laeger; 1993 Aug; 155(31):2387-91. PubMed ID: 8346588
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin intranasal--unigene: Salcatonin intranasal--unigene.
Drugs R D; 2004; 5(2):90-3. PubMed ID: 15293868
[TBL] [Abstract][Full Text] [Related]
5. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of calcitonin in the prevention and treatment of osteoporosis.
Halkin V; Reginster JY
BioDrugs; 1998 Oct; 10(4):295-300. PubMed ID: 18020602
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin for prevention and treatment of osteoporosis.
Reginster JY
Am J Med; 1993 Nov; 95(5A):44S-47S. PubMed ID: 8256795
[TBL] [Abstract][Full Text] [Related]
8. Effect of salcatonin given intranasally on early postmenopausal bone loss.
Overgaard K; Riis BJ; Christiansen C; Hansen MA
BMJ; 1989 Aug; 299(6697):477-9. PubMed ID: 2507027
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin therapy in osteoporosis.
Muñoz-Torres M; Alonso G; Raya MP
Treat Endocrinol; 2004; 3(2):117-32. PubMed ID: 15743107
[TBL] [Abstract][Full Text] [Related]
10. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
Ellerington MC; Hillard TC; Whitcroft SI; Marsh MS; Lees B; Banks LM; Whitehead MI; Stevenson JC
Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
[TBL] [Abstract][Full Text] [Related]
11. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
[TBL] [Abstract][Full Text] [Related]
13. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
[TBL] [Abstract][Full Text] [Related]
14. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
Flicker L; Hopper JL; Larkins RG; Lichtenstein M; Buirski G; Wark JD
Osteoporos Int; 1997; 7(1):29-35. PubMed ID: 9102059
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin.
Silverman SL
Rheum Dis Clin North Am; 2001 Feb; 27(1):187-96. PubMed ID: 11285994
[TBL] [Abstract][Full Text] [Related]
16. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
18. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin.
Silverman SL
Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
[TBL] [Abstract][Full Text] [Related]
20. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
Rizzoli R; Sigaud A; Azria M; Herrmann FR
Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
